Business
Almaden Minerals Announces Extension of Cure Period for NYSE American Listing
VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”; TSX: AMM; NYSE American: AAU) announces that,
About this update from Almaden Minerals Ltd.
[{"type":"text","content":" VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”; TSX: AMM; NYSE American: AAU) announces that, further to its press release of April 21, 2023, it has received an extension of its cure deadline from October 19, 2023 to April 19, 2024 (“New Cure Deadline”). As previously announced, Almaden is not in compliance with the continued listing standards of the NYSE American exchange because the Company’s securities have been selling for a low price per share for a substantial period of time which NYSE American determines to be a 30-trading-day average price of less than US$0.20 per share. The Company’s continued listing on the NYSE American exchange is predicated on it demonstrating sustained price improvement within a reasonable period of time which the staff has determined to be no later than April 19, 2024. Almaden is considering its alternatives with respect to the requirement that it regain compliance with the NYSE American’s continued listing standards within the New Cure Deadline. On Behalf of the Board of Directors, “J. Duane Poliquin” J. Duane PoliquinChairAlmaden Minerals Ltd. Safe Harbor Statement Certain of the statements and information in this news release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian provincial securities laws. All statements, other than statements of historical fact, are forward-looking statements or information. Forward-looking statements or information in this news release relate to, among other things, the Company’s continued trading on the NYSE American and Toronto Stock Exchanges, the length of the cure period, and the Company’s ability to consider and pursue alternatives that would allow it to regain compliance with the NYSE American continued listing standards. These forward-looking statements and information reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant legal, regulatory, business, operational and economic uncertainties and contingencies, and such uncertainty g...